K-biotech 2026 is having a moment that few people outside the pharmaceutical industry saw coming. Every January, the world’s most powerful pharma executives gather in San Francisco for the JPMorgan Healthcare Conference. In 2026, something unusual happened: the Korean booths were packed. Representatives from ABL Bio, Alteogen, and Orum Therapeutics were fielding calls from Big Pharma before the event even officially opened. Meanwhile, headlines back in Seoul announced a record-breaking milestone. Korea’s drug industry had logged $14.5 billion in technology out-licensing deals in 2025—nearly triple the previous year’s figure. In short, K-biotech 2026 is no longer a niche story. It has become one of the most compelling narratives in global life sciences.
For most foreign observers, South Korea still conjures images of Samsung smartphones and K-pop. However, a quieter revolution has been underway in Daejeon, Seongnam, and Seoul. Korean biotech companies 2026 are not just making drugs. Instead, they are building the platforms that global pharmaceutical giants pay billions to access. In this article, we break down what these three companies are doing—and why Big Pharma is paying close attention.
The $14.5 Billion Wake-Up Call for the Korea Biotech Industry
For years, South Korea’s biotech reputation rested on two pillars: contract manufacturing and biosimilars. Companies like Samsung Biologics and Celltrion dominated those lanes. However, the Korea biotech industry has quietly shifted gears. In 2025, Korean pharma firms exported $14.5 billion worth of licensed technologies, according to the Korea Pharmaceutical and Bio-Pharma Manufacturers Association. That is up sharply from $5.5 billion the previous year.
To put that in perspective, Korea’s technology export figure now rivals the total biotech venture investment across entire regions of Europe. In addition, the South Korean government launched the National Bio Committee in January 2025. This presidential advisory body oversees national biotechnology and life sciences strategy. That kind of top-down political backing rarely goes unnoticed by global investors.
Importantly, this growth is not built on imitation. The deals flowing out of South Korea in 2025 and 2026 are for original platform technologies. Specifically, they include novel drug delivery systems, antibody engineering approaches, and molecular mechanisms that no one else has commercialized at scale. As a result, the Korea biotech industry has earned a new label: a top-three supplier of core technology to Big Pharma.
Three companies stand at the center of this transformation. Each represents a different bet on the next chapter of drug development. Furthermore, each has already convinced the world’s most demanding pharmaceutical buyers to write very large checks.
ABL Bio: Opening a Door the Brain Slammed Shut
The Problem That Stumped Pharma for Decades
The human brain is protected by one of biology’s most effective security systems: the blood-brain barrier, or BBB. This wall of cells keeps toxins and pathogens out of the central nervous system. Unfortunately, it also keeps most medicines out. For decades, drug developers working on Alzheimer’s and Parkinson’s disease have faced a brutal reality. Their promising compounds simply cannot reach the organ they are designed to treat.
Consequently, neurodegenerative disease remains one of the most underfunded areas in drug development. Treatments that work brilliantly in a lab often fail catastrophically in human trials. In many cases, the drug is not ineffective—it simply never makes it to the brain. The South Korea biopharma sector found an unusually elegant answer to this problem. That answer came from a company in Seongnam called ABL Bio.
Grabody-B: The Solution GSK Paid $2.8 Billion For
ABL Bio’s solution is a platform technology called Grabody-B. In essence, it is a molecular shuttle. It works by engineering a bispecific antibody that binds to the insulin-like growth factor 1 receptor, or IGF1R, which sits on the cells lining the blood-brain barrier. By latching onto IGF1R, the antibody effectively hitches a ride across the barrier—carrying its therapeutic payload directly into the brain.
What makes this approach genuinely exciting is its versatility. Grabody-B was initially developed for antibodies. However, ABL Bio has since demonstrated that it can also shuttle RNA-based therapies—including siRNA and antisense oligonucleotides—into the brain. That significantly expands the range of diseases and drug types the platform can address. In other words, Grabody-B is not a single-use tool. It is a flexible delivery engine with growing potential applications.
In April 2025, ABL Bio announced a worldwide licensing agreement with GSK. Under the deal, GSK gained rights to apply Grabody-B across multiple undisclosed CNS targets. GSK takes responsibility for preclinical development through to commercialization. The total deal value, including milestone payments and royalties, could reach £2.07 billion—approximately $2.8 billion. ABL Bio received £38.5 million upfront.
Crucially, ABL Bio retained rights to two of the most commercially coveted Alzheimer’s targets—amyloid-beta and tau. By November 2025, Eli Lilly had also entered discussions with ABL Bio. Furthermore, the platform had already attracted Sanofi in 2022 for Parkinson’s-focused programs. As a result, ABL Bio is not a one-deal company. It is a platform business that multiple global pharma firms are now actively queuing up to access.
For more on Korean startups tackling neurological diseases, see our earlier coverage of Top Neurology Startups in Korea.
Alteogen: Rethinking How Drugs Enter Your Body
Why the IV Drip Is Going Away
Picture a cancer patient sitting in an infusion center for three to four hours. An IV drip slowly delivers medication into their bloodstream. This has been standard care for countless biologic drugs—but it is expensive, time-consuming, and deeply uncomfortable for patients already dealing with serious illness.
For pharmaceutical companies, there is an additional problem. IV infusion centers are a bottleneck. Every patient who needs a biologic drug must be scheduled, monitored, and released afterward. As biologic therapies become more common, that model does not scale. The most obvious solution is converting IV drugs into subcutaneous injections—shots that patients can receive in minutes, or eventually administer at home.
However, converting a biologic from IV to subcutaneous is not straightforward. Large-molecule drugs require volume that the subcutaneous space cannot easily accommodate. For years, this was viewed as an unsolvable constraint. Alteogen, a biotech company based in Daejeon, decided to solve it anyway.
ALT-B4 and the Subcutaneous Revolution
Alteogen’s core platform is called Hybrozyme. Its key component is a recombinant human hyaluronidase enzyme called ALT-B4. The mechanism is elegant. ALT-B4 temporarily breaks down hyaluronic acid in the skin. Consequently, this creates a temporary expansion of the subcutaneous space. Large drug volumes can then disperse and absorb efficiently. Once absorbed, the tissue returns to normal. In short, Alteogen has created a molecular key that unlocks the body’s subcutaneous compartment.
The commercial implications have proven enormous. Merck’s blockbuster cancer drug Keytruda now has a subcutaneous version, Keytruda Qlex, that uses Alteogen’s ALT-B4 technology. In addition, AstraZeneca signed a deal worth up to $1.35 billion to use the platform. GSK’s subsidiary Tesaro followed with a licensing deal for dostarlimab worth up to $265 million. Most recently, in March 2026, Biogen signed an exclusive license agreement covering two undisclosed biologics—with milestone potential reaching $549 million.
By early 2026, Alteogen had inked licensing agreements with six global pharmaceutical companies. At JPMorgan 2026, CEO Jeon Tae-yeon told reporters that an additional deal was “very imminent.” Moreover, the company was simultaneously in talks with approximately ten partners. Alteogen’s preliminary 2025 revenue came in at roughly $141 million—more than double the prior year—with operating profit up nearly 275 percent.
This is, in many ways, the most commercially proven K-biotech 2026 story. The technology works. The royalties are arriving. Furthermore, the pipeline of future deals continues to grow. Alteogen is also planning to transfer its listing from the tech-heavy Kosdaq to Korea’s main Kospi exchange. Notably, that move signals growing confidence in its long-term stability as a business.
For more on how Korean drug platforms are reshaping the global pharma landscape, see our piece on Drug Discovery Startups in Korea.
Orum Therapeutics: Building Tomorrow’s Cancer Drug in Daejeon
What Is a Degrader-Antibody Conjugate?
The history of cancer treatment is a history of getting more precise. Chemotherapy kills cancer cells—but it also kills healthy cells. Targeted therapies improved the picture significantly. Nevertheless, many cancer-driving proteins remain “undruggable.” They sit inside the cell where conventional drugs cannot reach them. Antibody-drug conjugates, or ADCs, were the next major leap. They attach a toxic payload to an antibody that homes in on cancer cells, so the poison arrives exactly where needed.
Orum Therapeutics, founded in 2016, has engineered what it calls the generation beyond ADCs. Its platform, TPD²®, creates Degrader-Antibody Conjugates, or DACs. Instead of delivering a poison that kills cancer cells, DACs deliver a molecular degrader. This compound hijacks the cell’s own protein disposal system—the E3 ubiquitin ligase pathway—to eliminate disease-causing proteins from within. In simple terms, Orum’s drugs do not just poison cancer cells. They reprogram the cancer cell to destroy itself from the inside.
The key advantage is precision. Because the degrader payload arrives via an antibody targeting specific cancer cells, healthy cells are largely spared. Furthermore, the mechanism works catalytically—one degrader molecule can destroy many copies of a target protein. As a result, potent effects are achievable at lower doses.
From Korea to Bristol Myers Squibb and Beyond
Orum’s commercial track record is already impressive for its age. In October 2023, the company licensed its AML drug candidate ORM-6151 to Bristol Myers Squibb in a deal worth up to $180 million, including a $100 million upfront payment. That is an unusually large sum for an early-stage asset. Subsequently, in July 2024, Vertex Pharmaceuticals signed a multi-target licensing agreement for Orum’s TPD platform, paying $15 million upfront.
In February 2025, Orum completed its IPO on Kosdaq—the first biotech IPO in Korea that year under the technology-specialized listing program. By December 2025, the company had raised an additional $100 million in convertible preferred stock. New investors included Weiss Asset Management from Boston and Korea Investment Partners. Orum then presented preclinical data on ORM-1153—a novel DAC targeting CD123 for acute myeloid leukemia—at the AACR Annual Meeting in 2026. Notably, the company operates from dual hubs in Daejeon and Lexington, Massachusetts, making it one of the very few Korean biotechs with a real operational footprint in the United States.
At JPMorgan 2026, CEO Lee Sung-ju framed the company’s ambition clearly. The goal is not simply to collect milestone payments. It is to become what he called “a next-generation anticancer specialist with global attention.”
For context on how Korea’s startup ecosystem supports companies like Orum, see our Guide to the Korean Startup Ecosystem.
The Korea Advantage: Why Korean Biotech Keeps Winning
At this point, it is worth asking an obvious question: why Korea? South Korea does not have a Pfizer or a Roche. It does not have the deep VC ecosystem of Boston or San Diego. For most of its history, its pharmaceutical sector was a generic-drug economy. So how did it produce three companies capable of negotiating with the world’s most sophisticated pharma buyers?
First, Korea’s clinical trial infrastructure is exceptional. Seoul ranked as the city with the greatest number of pharma-led clinical trials in the world in 2022. As a result, Korean companies can generate high-quality clinical data more efficiently than counterparts in many other markets.
Second, Korea’s research universities have produced a generation of scientists who trained partly in the United States and then returned home to build companies. In particular, KAIST—the Korea Advanced Institute of Science and Technology—has been a consistent seedbed for biotech founders. ABL Bio’s Grabody-B, Orum’s DAC platform, and Alteogen’s Hybrozyme all trace roots to academic research collaborations in Korea.
Third, the South Korean government has backed the sector in a sustained and targeted way. In addition to the National Bio Committee launched in 2025, the Ministry of Science and ICT announced the National Synthetic Biology Initiative in late 2024. Consequently, Korean biotechs have had a longer runway to develop their platforms than they might have in a purely market-driven environment.
Finally, there is a strategic mindset factor. Korean biotech companies have largely embraced a licensing-first model—developing proprietary platforms and out-licensing them to global pharma partners, rather than attempting to commercialize drugs independently. This approach matches their current scale and expertise. Moreover, it generates significant upfront and milestone revenue. It has proven enormously effective, even as analysts debate whether Korea’s next step should be toward full independent commercialization.
Risk and Reality: The Challenges Ahead
No investment story is complete without an honest accounting of risks. For all its momentum, K-biotech 2026 faces real structural challenges.
The most pressing issue is capital scarcity at the early stage. Since mid-2022, rising interest rates have sharply reduced venture investment in early-stage Korean biotech ventures. Industry veterans warn that the current wave of licensing deals reflects companies built in an earlier, more capital-rich environment. Accordingly, the pipeline of future stars may be thinner than it looks. KAIST professors have publicly warned that without better early-stage funding, Korea could face a pipeline gap within three to five years.
There is also the question of royalty expectations. When Alteogen’s Keytruda Qlex royalty rate was disclosed at approximately two percent—below the four to five percent many analysts had assumed—the company’s stock fell over twenty percent in a single day. Roughly $4.2 billion in market value disappeared within two trading sessions. The episode is a useful reminder that total deal value and actual cash flow are very different numbers.
Furthermore, Korean regulatory frameworks have not kept pace with the speed of biotech innovation. The Korea Bio Association has called on policymakers to prioritize flexible listing criteria and R&D tax credits. Nevertheless, the government’s track record of acting decisively on strategic industries offers reason for cautious optimism. Additionally, the National Bio Committee’s mandate explicitly includes reducing regulatory friction—which suggests reform may arrive sooner than skeptics expect.
For more on the earlier generation of Korean biotech startups working on cancer, see our coverage of Biotech Startups in Korea Helping to End Cancer.
The Bottom Line
K-biotech 2026 is not a hype cycle. ABL Bio has GSK and Eli Lilly paying for access to its brain-drug shuttle. Alteogen has six global pharmaceutical companies licensing its subcutaneous conversion technology. Orum Therapeutics has BMS and Vertex investing in a cancer-drug platform built on entirely new biological principles. These are not promises—they are signed contracts with the world’s most rigorous drug developers.
In many respects, the emergence of these three companies mirrors patterns seen in earlier Asian biotech waves. South Korea’s combination of elite scientific talent, robust clinical infrastructure, government backing, and a pragmatic licensing model has created companies genuinely capable of reshaping drug development. However, whether the Korea biotech industry can sustain this momentum—while navigating capital constraints and regulatory friction—will be one of the most important stories in global life sciences over the next five years.
For now, the direction of travel is unmistakably clear. When Big Pharma needs a drug delivered to a brain, a shot to replace an IV drip, or a smarter way to destroy cancer from the inside, it increasingly picks up the phone and calls Korea.
